<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784572</url>
  </required_header>
  <id_info>
    <org_study_id>10477M-EVADOULIM</org_study_id>
    <nct_id>NCT04784572</nct_id>
  </id_info>
  <brief_title>Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry</brief_title>
  <acronym>evadoulim</acronym>
  <official_title>Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de Ville-Evrard, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de Ville-Evrard, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since psychiatry is still too often confronted with a dichotomy between psyche and soma, the&#xD;
      assessment of pain and anxiety at RMI is still rarely done (Willer et al., 1982). The&#xD;
      objective of this exploratory study is to evaluate the influence of pharmacological factors&#xD;
      (type of injected molecules, injection frequency, injection site, treatment duration,&#xD;
      treatment dose, time since last injection) and individual about the pain perceived when&#xD;
      injecting antipsychotic therapy (diagnosis, sex, age, weight, duration of illness, level of&#xD;
      anxiety, psychiatric and somatic comorbidity, insight). In the future, this study will&#xD;
      develop a suitable procedure to limit pain and anxiety during RMI. Taking these dimensions&#xD;
      into account will probably allow a better compliance of patients for this type of care, and&#xD;
      thus a decrease in the number of relapses in the long term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">January 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The group will have a first injection delay and then a second injection delay.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Digital Scale of Pain (END)</measure>
    <time_frame>5 seconds</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Facial Anxiety Visual Scale (EVAf)</measure>
    <time_frame>10 seconds</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insight scale</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">393</enrollment>
  <condition>Delayed Antipsychotic Treatment, Pharmacological Factors and Individual Factors</condition>
  <arm_group>
    <arm_group_label>First injection delay and second injection delay</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses.&#xD;
During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>first injection delay and second injection delay</intervention_name>
    <description>During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes.&#xD;
The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance.</description>
    <arm_group_label>First injection delay and second injection delay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (Males, Females)&#xD;
&#xD;
          -  Over the age of 18&#xD;
&#xD;
          -  Hospitalized or outpatient&#xD;
&#xD;
          -  Patient affiliated with social security, State Medical Aid (AME)&#xD;
&#xD;
          -  With prescription of antipsychotic delay by intramuscular injection&#xD;
&#xD;
          -  French language mastered&#xD;
&#xD;
          -  Given oral consent to pass the self-assessment scales&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients on long-term analgesic treatment, daily&#xD;
&#xD;
          -  Patients with chronic pain with or without analgesic treatment&#xD;
&#xD;
          -  Patient not communicating&#xD;
&#xD;
          -  Pregnant woman, parturint and nursing mother&#xD;
&#xD;
          -  Person deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Minor and person subject to legal protection: guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ch Ville Evrard</name>
      <address>
        <city>Neuilly-sur-Marne</city>
        <zip>93330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de Ville-Evrard, France</investigator_affiliation>
    <investigator_full_name>Januel</investigator_full_name>
    <investigator_title>HEAD OF THE UNIT OF CLINICAL RESEARCH</investigator_title>
  </responsible_party>
  <keyword>pain -injection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

